Business
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
"Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune ...
About this update from Innocan Pharma Corporation
[{"type":"text","content":"Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial\"Lady\", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis.Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps.Lady was administered Innocan's liposomal CBD injection and experienced significant improvement, which lasted more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 21, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the \"Company\" or \"Innocan\"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report another clinical success in its Canine (dogs) Compassionate Care Trial, resulting in improving walking abilities and significant decrease in pain in participating canines. \"Lady\", an 11-year-old spayed dachshund-mixed dog was suffering from severe autoimmune mediated polyarthritis that resulted in an almost complete inability to walk, accompanied by severe pain and an overall disability. Figure 1 \"Lady\"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/6922/155502_6846c17cc43a8ba8_001full.jpgCannot view this video? Visit:https://www.youtube.com/watch?v=MGm4GANhqUULady was treated with joint supplements (Glycoflex), steroids, and hydrotherapy, but was still very lame and incapable of walking more than a few steps. In December 2022, as part of the Company's Compassionate Care Trial, Lady was administered Innocan's liposomal CBD injection, in addition to all other treatments. Following injection, Lady demonstrated noticeable improvement, walking longer distances and much faster than she had been previously. The improvement in Lady's condition lasted for more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.\"We couldn't be more thrilled than to be able to assist a poor creature in pain,\" said CEO Iris Bincovich, \"2023 started with rapid clinical and IP performance, igniting the hope that we are getting closer to advanced availability of treatments. We believe that our ability to help Lady w...